FGFR1 and non-small cell lung carcinoma: A similar outcome was reported by basket- or umbrella-type clinical trials in FGFR1-amplified advanced cancers; Sq-NSCLC had diverse sensitivity to FGFRis; SD was the best response to LY2874455 (a pan-FGFR1–4 inhibitor that occupies the ATP-binding pocket in the kinase domain, NCT01212107) (8), Debio-1347 (CH5183284, an ATP competitive, highly selective inhibitor of FGFR1–3, NCT01948297) (50), and derazantinib (ARQ 087, an ATP-competitive pan-FGFRi with multikinase activity, NCT01752920) (51).